Bladder Cancer Clinical Practice Guideline Diagnosis Evidenced-based Medicine Treatment.

*Ejaculation Humans Male Prostatic Hyperplasia/complications Prostatism/etiology Randomized Controlled Trials as Topic Sexual Dysfunction Physiological/*etiology/physiopathology Urologic Surgical Procedures Male/*adverse effects benign prostatic hyperplasia decreased ejaculation ejaculatory dysfunction lower urinary tract symptoms painful ejaculation retrograde ejaculation

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Androgen Antagonists/*therapeutic use Humans Male Observational Studies as Topic Prostatic Neoplasms/*drug therapy Risk Assessment Urinary Bladder Neoplasms/epidemiology/*prevention & control Androgen deprivation therapy Bladder cancer Pharmacoepidemiology Prostate cancer Systematic review

膀胱肿瘤 光动力诊断 白光成像 Meta分析